Notice of Results

Oxford Biomedica PLC
07 August 2007


For immediate release                                              7 August 2007


                                OXFORD BIOMEDICA
                           NOTICE OF INTERIM RESULTS
                     FOR THE SIX MONTHS ENDED 30 JUNE 2007

                           Date: 11 September 2007



Oxford, UK - 7 August 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announces that it will be releasing its interim results for the six
months ended 30 June 2007 on Tuesday 11 September.


Analyst Briefing:

An analyst briefing will be held at 10:00 am on 11 September at the offices of
Buchanan Communications, 45 Moorfields, London EC2.


Web cast:

Simultaneously to the analyst briefing at 10.00 am, there will be a live audio
web cast of the results presentation.

To connect to the web cast facility, please go to the Company's website: 
http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the 
start of the briefing. This will also be available for replay shortly after the
presentation.

                                      -Ends-


For further information, please contact:

Oxford BioMedica plc:                                   Tel: [phone]
Professor Alan Kingsman, Chief Executive

City/Financial Enquiries:                               Tel: [phone]
Lisa Baderoon/Mary-Jane Johnson Buchanan Communications

Scientific/Trade Press Enquiries:                       Tel: [phone]
Katja Stout/ Susan Yu/ Gemma Bradley
Northbank Communications


Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development and commercialisation of novel therapeutic vaccines and gene-based
therapies with a focus on oncology and neurotherapy. The Company was established
in 1995 as a spin-out from Oxford University, and is listed on the London Stock
Exchange.


The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. In oncology, the lead product candidate
is TroVax(R), an immunotherapy for multiple solid cancers, which is licensed to
sanofi-aventis for global development and commercialisation. A Phase III trial
of TroVax in renal cancer is ongoing and sanofi-aventis is implementing a
development plan for colorectal cancer. Oxford BioMedica's oncology pipeline
includes a specific immunotherapy candidate, Hi-8(R) MEL, for melanoma, which
has completed two clinical trials. In neurotherapy, the Company's lead product,
ProSavin(R), is expected to enter clinical development for Parkinson's disease
in 2007. The neurotherapy pipeline also includes preclinical gene-based
therapeutics for vision loss, motor neuron disease and nerve repair.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 80 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners
include sanofi-aventis for TroVax and Wyeth for the targeted antibody therapy.
The Company also has collaborations with Sigma-Aldrich, MolMed and Virxsys.
Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and
Pfizer.


Further information is available at www.oxfordbiomedica.co.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange